|AHFS/Drugs.com||International Drug Names|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||231.29358 g·mol−1|
|3D model (JSmol)|
Aminophenazone (or aminopyrine, amidopyrine, Pyramidon) is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of cytochrome P-450 metabolic activity in liver function tests. It is also used in measuring the total body water in the human body system. Production and use have been banned in France, Thailand and India.
Aminophenazone was first synthesized by Friedrich Stolz and Ludwig Knorr in the late nineteenth century, and sold as an anti-fever medicine known as Pyramidon by Hoechst AG from 1897 until its eventual replacement by the safer propyphenazone molecule.
Symptoms of exposure to this compound include:
Agranulocytosis often occurs. Ingestion may cause central nervous system stimulation, vomiting, convulsions, cyanosis, tinnitus, leukopenia, kidney damage and coma. Ingestion may also lead to nausea, mental disturbances, methemoglobinemia, chocolate-colored blood, dizziness, epigastric pain, difficulty in hearing, thready pulse and liver damage.
Chronic symptoms include:
When heated to decomposition this compound emits toxic fumes of nitrogen oxides.
Amidopyrine is metabolized by demethylation and acetylation. Amidopirina metabolites are 4-aminoantipyrine, metilaminoantipirin, rubazonovaya and metilrubazonovaya acid. These acids have a reddish color. Due to the presence in the urine of these acids makers amidopirina high doses, it can have a reddish brownish coloration.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|